Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capmatinib + Osimertinib vs Chemo in EGFR-mutated MET-amplified NSCLC
NCT04816214Phase 3Terminated
- Sponsor
- Novartis
- Start
- Sep 2021
- Primary completion
- Dec 2022
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 3
01
Overview
A Phase 3 trial of capmatinib in non-small cell lung cancer (NSCLC), sponsored by Novartis. Started Sep 2021; status: terminated.
02
Drugs
capmatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04816214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04816214.